embecta looks like a bargain

Article Excerpt

EMBECTA CORP. $19 is a spinoff buy. The company (Nasdaq symbol EMBC; Manufacturing & Industry sector; Shares outstanding: 57.3 million; Market cap: $1.1 billion; Dividend yield: 3.2%; Takeover Target Rating: Medium; www.embecta.com) took its current form in April 2022 when Becton Dickinson & Co. (New York symbol BDX) spun off its Diabetes Care business. Investors received one share of embecta for every five common shares of Becton they held. In its fiscal 2023 third quarter, ended June 30, 2023, revenue fell 1.7%, to $286.1 million from $291.1 million a year earlier, partly due to lower sales to its former parent company. Excluding unusual items, embecta earned $0.69 a share (or a total of $39.8 million) in the quarter (it did not provide a comparable year-earlier figure). The company should earn about $2.78 a share for all of fiscal 2023. The stock is down 56% since the spinoff, which is why it trades at just 6.8 times that estimate. That’s a reasonable p/e as embecta invests 8%…